Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Conditions

• Lichen Plano-Pilaris

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Nemolizumab — DRUG
  subcutaneous injection

Study Details

Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.

Key Dates

Start date

Feb 1, 2026

Status verified

Feb 2026

Primary completion

Jun 30, 2027

Completion

Jun 30, 2027

Study Design

Enrollment

10 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Patients receive nemolizumab injections every 4 weeks, weight based dosing

Primary Outcome Measure

Change from baseline at 24 weeks in Lichen Planopilaris Activity Index (LPPAI) [ Time Frame: 24 weeks ]

Central Contacts

• Peter Friedman, MD PhD
  8453520500
  [email protected]

Locations (1)

Find similar trials in New City, NY